Kinetics of cEVs Over the 24-hour Dosing Interval After Low-dose Aspirin Administration
NCT ID: NCT05584943
Last Updated: 2022-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
93 participants
OBSERVATIONAL
2015-09-21
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes
NCT05105919
Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II
NCT05702463
A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
NCT00501059
Study to Evaluate How Patients Regard the Benefits and Risks of Low-dose Aspirin for the Prevention of Heart and Blood Vessels Disease and for the Prevention of Cancer of the Colon and Rectum
NCT03603366
Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease
NCT02370680
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
84 patients on ASA chronic treatment
A total of 84 patients on chronic treatment with low-dose ASA (enteric coated, Cardio aspirin 100 mg/die Bayer, Milan, Italy) once daily (o.d.) for at least 1 month
No interventions assigned to this group
Healthy subject
9 healthy subjects, not on ASA treatment, as controls.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* arterial hypertension if well controlled with stable drug therapy
* hypercholesterolemia if well controlled with stable drug therapy
Exclusion Criteria
* clinically significant hepatic insufficiency
* clinically significant renal insufficiency
* clinically significant cardiac insufficiency
* clinically significant pulmonary insufficiency
* history of malignant neoplasms (diagnosed and treated within the past 5 years)
* pregnancy or lactation
* history of malabsorption
* regular (daily) alcohol consumption
* regular (i.e., more than 3 days per week) non steroidal anti-inflammatory drug intake
* type 1 diabetes excluded by islet autoantibodies evaluation (anti-glutamic acid decarboxylase, islet cell cytoplasmic, and IA-2 antibodies), family history of type 1 diabetes, age lower than 40 years, lean phenotype, early requirement for insulin therapy
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
G. d'Annunzio University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Francesca Santilli
Associate Professor of Internal Medicine, Department of Medicine and Aging, Head of Thrombosis and Hemostasis Unit
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EvASA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.